文献速递复苏、休克与脓毒症心脑血管急症

PAD2通过瓜氨酸化SERCA2a蛋白扰乱失血性休克诱导心律失常时心肌细胞钙稳态

PAD2 disturbs cardiomyocyte calcium homeostasis by citrullinating SERCA2a protein in hemorrhagic shock induced arrhythmia.
PubMed 文献 · J Trauma Acute Care Surg · 2025-05-01
一句话结论失血性休克心肌缺氧时PAD2瓜氨酸化SERCA2a降低其活性、破坏钙稳态;PAD2基因缺失或抑制可改善室性心律失常并提高生存率(动物与患者血样研究)。

该基础研究检测失血性休克患者外周血PAD2蛋白水平升高,并构建Pad2基因敲除小鼠与失血性休克模型。缺氧时PAD2与肌浆网共定位增加,通过瓜氨酸化抑制SERCA2a活性,扰乱心肌细胞钙稳态。AAV9介导心肌PAD2过表达加重失血性休克后生存率与室性心律失常发生率;PAD2酶活性突变及PAD2特异性抑制剂腹腔注射则改善生存率并减少心律失常。作者结论为PAD2基因缺陷或抑制可改善失血性休克后室性心律失常并提高生存。

要点

  • 失血性休克患者外周血PAD2蛋白水平显著升高(ELISA检测)。
  • Pad2基因敲除改善小鼠心肌细胞肌浆网钙稳态并减轻休克后心律失常。
  • 缺氧时PAD2与肌浆网共定位增加,通过瓜氨酸化抑制SERCA2a活性。
  • 心肌AAV9-PAD2过表达加重小鼠失血性休克后生存率与室性心律失常发生率。
  • PAD2酶活性突变及PAD2特异性抑制剂腹腔注射改善小鼠失血性休克后生存率并减少心律失常。

适用人群与场景

  • 失血性休克患者(仅采集外周血检测PAD2蛋白水平)
  • 失血性休克小鼠模型(股动脉置管放血构建)

处置流程与药物剂量

  • PAD2特异性抑制剂经腹腔注射用于失血性休克小鼠,可改善生存率并减少心律失常(原文未写明药名、剂量与疗程)
  • PAD2酶活性突变经腹腔注射用于失血性休克小鼠,可改善生存率并减少心律失常
  • AAV9-PAD2经尾静脉注射用于小鼠心肌PAD2体内过表达(研究工具,非治疗推荐)

研究设计与关键结果

  • 研究类型为基础科学研究(original research-basic sciences research),包含失血性休克患者外周血样本、Pad2基因敲除小鼠、心肌细胞体外实验及AAV9心肌过表达小鼠。
  • 失血性休克患者外周血PAD2蛋白水平显著升高(ELISA)。
  • Pad2敲除改善小鼠心肌细胞肌浆网钙稳态并减轻休克后心律失常。
  • 缺氧后PAD2与肌浆网共定位增加,并通过瓜氨酸化抑制SERCA2a活性。
  • AAV9介导心肌PAD2过表达加重小鼠失血性休克后生存率与室性心律失常发生率。
  • PAD2酶活性突变及PAD2特异性抑制剂腹腔注射改善小鼠失血性休克后生存率并减少心律失常。

证据类型、等级与局限

  • 证据类型:基础科学研究(original research-basic sciences research),证据等级:不适用(not applicable)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者结论认为,失血性休克心肌缺氧时PAD2通过瓜氨酸化降低SERCA2a酶活性、破坏心肌钙稳态,PAD2基因缺陷或抑制可改善室性心律失常并提高生存率。
  • 该研究为动物与体外实验,PAD2抑制剂的人体剂量、给药方案与疗效尚未在原文中给出。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Malignant arrhythmia induced by traumatic hemorrhage is a leading cause of early mortality in hemorrhagic shock. Understanding the mechanisms driving these arrhythmias and identifying therapeutic targets are critical for improving early survival in patients with traumatic hemorrhagic shock.

METHODS: Peripheral blood samples from patients with hemorrhagic shock were collected and analyzed for peptidylarginine deiminase 2 (PAD2) protein levels using ELISA. Pad2 knockout mice ( Pad2 -/- , Pad2 KO) were generated, and the hemorrhagic shock model was constructed via femoral artery cannulation and bloodletting. Cardiomyocytes were isolated and contractility and calcium content were measured by confocal microscopy. PAD2 subcellular localization was assessed through immunofluorescence and Western blotting. Proteins interacting with PAD2 in cardiomyocytes were identified using co-immunoprecipitation followed by mass spectrometry (CoIP-MS). The effect of PAD2 on sarcoplasmic reticulum calcium-ATPase 2a (SERCA2a) activity and citrullination was evaluated through enzyme activity assays and protein citrullination detection. AAV9-PAD2 was injected into mice via tail vein to induce in vivo overexpression of PAD2 in the myocardium. The effects of PAD2 enzymatic activity mutations and a PAD2-specific inhibitor on survival rate and arrhythmia following hemorrhagic shock were assessed through intraperitoneal injection.

RESULTS: PAD2 protein levels were significantly elevated in the peripheral blood of patients with hemorrhagic shock. Pad2 knockout improved calcium homeostasis in the sarcoplasmic reticulum of cardiomyocytes and alleviated post-shock arrhythmia in mice. Following hypoxia, PAD2 exhibited increased colocalization with the sarcoplasmic reticulum. During hypoxia, PAD2 inhibited SERCA2a activity through citrullination. AAV9-mediated overexpression of PAD2 in cardiomyocytes worsened both survival rates and the incidence of ventricular arrhythmia following hemorrhagic shock in mice. Conversely, PAD2 enzymatic activity mutations and a PAD2-specific inhibitor improved survival rates and reduced arrhythmia after hemorrhagic shock.

CONCLUSION: During myocardial hypoxia occurs in hemorrhagic shock, PAD2 reduces SERCA2a enzyme activity by citrullination, disrupting myocardial calcium homeostasis. Peptidylarginine deiminase 2 gene deficiency or inhibition improves ventricular arrhythmias and increases survival following hemorrhagic shock.

LEVEL OF EVIDENCE: Original Research-basic sciences research; not applicable.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Gan L, Li R, Wang Q, et al. PAD2 disturbs cardiomyocyte calcium homeostasis by citrullinating SERCA2a protein in hemorrhagic shock induced arrhythmia. J Trauma Acute Care Surg. 2025. PMID: 40307970. doi:10.1097/TA.0000000000004644

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。